Ubistezin release form. The drug 'Ubistezin' - instructions for use, description and reviews

If long-term surgical intervention on the face is required, a sensitivity reaction is observed to many local anesthetics; if the patient’s psyche is unstable, general anesthesia or sedation (medicated sleep) is used.

It is also possible to lubricate the tissues with an anesthetic. This method is well suited for treating young patients or for removing dental plaque. The drug is applied with a cotton swab. Very rarely anesthesia is used by electrophoresis or jet method, using an injector, electromagnet and laser, or freezing.

Local complications of local anesthesia in dentistry are short-lived. So, when using disposable needles, they very rarely, but can break. To prevent this from happening, the needle is not inserted to its full length.

To ensure that the patient does not feel pain during the injection, the anesthetic is administered very slowly. There are also nerve damages that slightly reduce sensitivity for a month. The frequency of this complication is about 20%. Sometimes spasm of the masticatory muscles may occur. It is associated with needle trauma to blood vessels. Tissue necrosis may also develop.

The advantages of local anesthesia in dentistry over anesthesia are obvious: in most cases, local anesthesia is easily tolerated, and the toxicity of local anesthetics is minimal.

However, there are cases when the use of general anesthesia is justified. This may be mask anesthesia, endotracheal or intravenous. For general anesthesia, the dental clinic must have a special permit. Most often, general anesthesia is used for dental implantation. Before general anesthesia, the patient undergoes an examination, as before an operation, doctors study his medical history in detail. Under general anesthesia, you can treat many diseased teeth at once and save time. General anesthesia is contraindicated for heart disease, stroke, asthma, diabetes, liver and kidney diseases with a significant decrease in their function, and pregnancy.

When administering pain relief, caution should be exercised in patients with diabetes mellitus and recent myocardial infarction.

Pain relief reinforces the normal response to dental treatment. Dentistry and pain today are incompatible concepts. Therefore, fewer and fewer people are afraid of dental treatment. You can always choose an anesthetic that suits you. The toxic novocaine is no longer used. The patient does not experience stress or negative emotions when visiting the dentist, and the doctor calmly performs all procedures. The success of treatment is determined not only by the extent to which new instruments and technologies are used, not only by the skills of the doctor, but also by the psychological mood of the patient. But it cannot be positive if the patient experiences fear. This factor is especially important during dental surgical interventions, since a person who is even slightly sensitive to pain and can easily tolerate dental treatment without anesthesia will not want to have teeth removed without pain relief. Especially when you need to install implants by implanting them into the bone. Most clinics use high-quality and safe imported drugs for pain relief. They can be used by pregnant women and do not contain adrenaline. Sedatives may also be used to calm you down. This is called premedication.

Registration number:

Trade patented name of the drug: UBISTESIN

Dosage form:
Solution for injection (with epinephrine)

Compound
1 ml contains:
active substances: articaine hydrochloride - 40 mg, epinephrine hydrochloride - 0,006 mg (equivalent to 0.005 mg of epinephrine)
Excipients: water for injection, sodium sulfite (equivalent to 0.31 mg SO2), sodium chloride.

Description
Transparent, colorless liquid.

Pharmacotherapeutic group
Local anesthetic + vasoconstrictor

ATX code: N018858

pharmachologic effect
Ubistezin is a combined drug for local anesthesia in dentistry. It contains articaine, a local anesthetic of the amide type of the thiaphene group. The effect of the drug begins quickly - after 1-3 minutes. The duration of anesthesia is at least 45 minutes. Wound healing proceeds without complications due to good tissue tolerance and minimal vasoconstrictor effect. Due to the low content of epinephrine in the drug, its effect on the cardiovascular system is weak: there is almost no increase in blood pressure and heart rate.
Pharmacokinetics. Articaine, when administered submucosally in the oral cavity, has a high diffusion ability. Protein binding is 95%. The active substances penetrate the placental barrier to a minimal extent, are practically not excreted in breast milk, and the half-life is 25 minutes.

Indications for use
Infiltration and conduction anesthesia in dentistry (especially in patients with concomitant severe somatic diseases), including when performing the following manipulations:

uncomplicated removal of one or more teeth;

filling carious cavities, grinding teeth before preparation. Contraindications

Hypersensitivity to articaine, epinephrine, sulfites, as well as to any of the auxiliary components of the drug;

paroxysmal tachycardia and other tachyarrhythmias;

bronchial asthma with hypersensitivity to sulfites;

angle-closure glaucoma, simultaneous use of non-selective beta-blockers;

severe form of liver failure (porphyria);

hyperthyroidism;

concomitant therapy with monoamine oxidase inhibitors or tricyclic antidepressants,

cardiogenic shock. Carefully used in the following cases:

chronic heart failure,

intraventricular and atrioventricular heart block,

inflammation in the area of intended anesthesia,

cholinesterase deficiency,

renal failure,

diabetes,

arterial hypertension,

childhood,

elderly age,

severe general condition, weakened patients. Use during pregnancy and lactation
It is possible to use the drug during pregnancy. If it is necessary to use the drug in a nursing mother, there is no need to interrupt feeding, since the active substances are not excreted in breast milk in clinically significant quantities. Directions for use and doses
For uncomplicated extraction of teeth in the upper jaw in the absence of inflammation, 1.7 ml of the drug (for each tooth) is usually injected into the submucosa in the area of the transitional fold on the vestibular side. In some cases, additional administration of 1 to 1.7 ml of the drug may be required to achieve complete anesthesia. In most cases, there is no need to perform painful injections on the palatal side. For anesthesia for palatal incisions and suturing to create a palatal depot, about 0.1 ml of the drug per injection is required. When removing several adjacent teeth, the number of injections can usually be limited. In the case of removal of mandibular premolars in the absence of inflammation, mandibular anesthesia can be dispensed with, because infiltration anesthesia provided by an injection of 1.7 ml per tooth is usually sufficient. If this way failed to achieve the desired effect, an additional injection of 1-1.7 ml of the drug should be performed into the submucosa in the area of the transitional fold of the mandible on the vestibular side. If in this case it was not possible to achieve complete anesthesia, it is necessary to block the mandibular nerve.
To prepare a tooth cavity for filling or treatment for the crown of any tooth, with the exception of the lower molars, administration of the drug in a dose of 0.5 to 1.7 ml for each tooth according to the type of infiltration anesthesia from the vestibular side is indicated. The exact amount depends on the desired depth and duration of the procedure. When performing one treatment procedure, adults can be administered up to 7 mg of articaine per 1 kg of body weight. The duration of anesthesia during which the intervention can be performed is 30-45 minutes. Side effect
The drug is usually well tolerated by patients, but the following side effects may develop:
From the central nervous system(depending on the size of the dose used): headache, disturbance of consciousness up to its loss, breathing problems up to its stop, muscle tremors, involuntary muscle twitching, sometimes progressing to generalized convulsions;
From the digestive organs: nausea, vomiting, diarrhea;
From the side of the organ of vision: rarely - “cloudness” in the eyes, transient blindness.
From the cardiovascular system: moderate hemodynamic disturbances, manifested in a decrease in blood pressure, tachycardia or bradycardia, depression of cardiovascular activity, which in extreme cases can lead to collapse and cardiac arrest, which threatens the patient’s life.
Allergic reactions: swelling or inflammation at the injection site; in other areas - redness of the skin, itching, conjunctivitis, rhinitis, angioedema of varying severity (including swelling of the upper and/or lower lip and/or cheeks, glottis with difficulty swallowing, urticaria, difficulty breathing). All these phenomena can progress to the development of anaphylactic shock.
Local reactions: swelling or inflammation at the injection site; the appearance of ischemic zones at the injection site (up to the development of tissue necrosis - with accidental intravascular injection);
Others: headaches are often observed, probably associated with the presence of epinephrine in the drug; other side effects caused by the action of epinephrine (tachycardia, arrhythmia, increased blood pressure) are extremely rare; nerve damage (up to the development of paralysis) - occurs only when the injection technique is violated. Overdose
Symptoms: dizziness, motor restlessness, impaired consciousness, decreased blood pressure, tachycardia, bradycardia.
Treatment: When the first signs of an overdose appear during injection, it is necessary to stop administering the drug, place the patient in a horizontal position, ensure clear airways, monitor heart rate and blood pressure. If breathing is impaired - oxygen, endotracheal intubation, artificial ventilation (central analeptics are contraindicated); for convulsions - slow intravenous short-acting barbiturates with simultaneous oxygen supply and hemodynamic control; in case of severe circulatory disorders and shock - intravenous infusion of solutions of electrolytes and plasma substitutes, glucocorticosteroids, albumin; with vascular collapse and increasing bradycardia - epinephrine 0.1 mg slowly intravenously, then intravenously by drip under the control of heart rate and blood pressure; for severe tachycardia and tachyarrhythmia - intravenous beta-blockers (selective); with increased blood pressure - peripheral vasodilators. Oxygen therapy and monitoring of blood circulation parameters are necessary in all cases. Interaction with other drugs
The hypertensive effect of sympathomimetic amines such as epinephrine can be enhanced by tricyclic antidepressants and monoamine oxidase inhibitors.
This type of interaction has been described for epinephrine and norepinephrine when used as vasoconstrictors at concentrations of 1:25,000 and 1:80,000, respectively.
The drug should not be prescribed during treatment with non-selective beta-blockers, since in this case there is a high risk of developing a hypertensive crisis and severe bradycardia.
The local anesthetic effect of articaine is enhanced and prolonged by vasoconstrictor drugs. special instructions
Ubistezin contains sulfites, which can increase the anaphylactic reaction.
The drug cannot be administered intravenously. Do not inject into the area of inflammation.
Eating is possible only after sensitivity has been restored.
To prevent infection (including hepatitis), it is necessary to always use new sterile syringes and needles each time a solution is taken from vials or ampoules. Opened cartridges must not be used again on other patients (risk of hepatitis).
Do not use a damaged cartridge.
Does not have a harmful effect on the fetus (with the exception of possible bradycardia) with any technique of application and dosage. Impact on the ability to drive vehicles and operate machinery.
In special tests, no clear effect of the drug on concentration and speed of motor reactions was revealed. However, due to the fact that the patient’s preoperative anxiety and stress caused by surgery can affect the effectiveness of the activity, the dentist must individually, in each specific case, decide on the patient’s permission to drive vehicles or operate machinery. Release form
Solution for injection with epinephrine in 1.7 ml cartridges; 50 cartridges each along with instructions for use in a metal container with a metal and plastic lid. Storage conditions
List B.
At a temperature not exceeding 25°C, in a place protected from light and out of reach of children. Best before date
2 years. Do not use after the expiration date stated on the package. Conditions for dispensing from pharmacies
On prescription Manufacturer and his address
ZM ESPE AG, Seefeld, Germany

Compound

1 ml contains:
active substances: articaine hydrochloride - 40 mg, epinephrine hydrochloride - 0,006 mg (equivalent to 0.005 mg of epinephrine)
Excipients: water for injection, sodium sulfite (equivalent to 0.31 mg SO2), sodium chloride.

Description

Transparent, colorless liquid.

Pharmacotherapeutic group

Local anesthetic + vasoconstrictor

ATX code

pharmachologic effect

Ubistezin is a combined drug for local anesthesia in dentistry. It contains articaine, a local anesthetic of the amide type of the thiaphene group. The effect of the drug begins quickly - after 1-3 minutes. The duration of anesthesia is at least 45 minutes. Wound healing proceeds without complications due to good tissue tolerance and minimal vasoconstrictor effect. Due to the low content of epinephrine in the drug, its effect on the cardiovascular system is weak: there is almost no increase in blood pressure and heart rate.
Pharmacokinetics. Articaine, when administered submucosally in the oral cavity, has a high diffusion ability. Protein binding is 95%. The active substances penetrate the placental barrier to a minimal extent, are practically not excreted in breast milk, and the half-life is 25 minutes.

Indications for use

Infiltration and conduction anesthesia in dentistry (especially in patients with concomitant severe somatic diseases), including during the following manipulations: uncomplicated removal of one or more teeth; filling carious cavities, grinding teeth before preparation.

Contraindications

Hypersensitivity to articaine, epinephrine, sulfites, as well as to any of the auxiliary components of the drug; paroxysmal tachycardia and other tachyarrhythmias; bronchial asthma with hypersensitivity to sulfites; angle-closure glaucoma, simultaneous use of non-selective beta-blockers; severe form of liver failure (porphyria); hyperthyroidism; concomitant therapy with monoamine oxidase inhibitors or tricyclic antidepressants, cardiogenic shock. Use with caution in the following cases: chronic heart failure, intraventricular and atrioventricular heart block, inflammation in the area of intended anesthesia, cholinesterase deficiency, renal failure, diabetes mellitus, arterial hypertension, childhood, old age, severe general condition, debilitated patients. Use during pregnancy and lactation
It is possible to use the drug during pregnancy. If it is necessary to use the drug in a nursing mother, there is no need to interrupt feeding, since the active substances are not excreted in breast milk in clinically significant quantities. Directions for use and dosage
For uncomplicated extraction of teeth in the upper jaw in the absence of inflammation, 1.7 ml of the drug (for each tooth) is usually injected into the submucosa in the area of the transitional fold on the vestibular side. In some cases, additional administration of 1 to 1.7 ml of the drug may be required to achieve complete anesthesia. In most cases, there is no need to perform painful injections on the palatal side. For anesthesia for palatal incisions and suturing to create a palatal depot, about 0.1 ml of the drug per injection is required. When removing several adjacent teeth, the number of injections can usually be limited. In the case of removal of mandibular premolars in the absence of inflammation, mandibular anesthesia can be dispensed with, because infiltration anesthesia provided by an injection of 1.7 ml per tooth is usually sufficient. If this way failed to achieve the desired effect, an additional injection of 1-1.7 ml of the drug should be performed into the submucosa in the area of the transitional fold of the mandible on the vestibular side. If in this case it was not possible to achieve complete anesthesia, it is necessary to block the mandibular nerve.
To prepare a tooth cavity for filling or treatment for the crown of any tooth, with the exception of the lower molars, administration of the drug in a dose of 0.5 to 1.7 ml for each tooth according to the type of infiltration anesthesia from the vestibular side is indicated. The exact amount depends on the desired depth and duration of the procedure. When performing one treatment procedure, adults can be administered up to 7 mg of articaine per 1 kg of body weight. The duration of anesthesia during which the intervention can be performed is 30-45 minutes.

Side effect

The drug is usually well tolerated by patients, but the following side effects may develop:
From the central nervous system(depending on the size of the dose used): headache, disturbance of consciousness up to its loss, breathing problems up to its stop, muscle tremors, involuntary muscle twitching, sometimes progressing to generalized convulsions;
From the digestive organs: nausea, vomiting, diarrhea;
From the side of the organ of vision: rarely - “cloudness” in the eyes, transient blindness.
From the cardiovascular system: moderate hemodynamic disturbances, manifested in a decrease in blood pressure, tachycardia or bradycardia, depression of cardiovascular activity, which in extreme cases can lead to collapse and cardiac arrest, which threatens the patient’s life.
Allergic reactions: swelling or inflammation at the injection site; in other areas - redness of the skin, itching, conjunctivitis, rhinitis, angioedema of varying severity (including swelling of the upper and/or lower lip and/or cheeks, glottis with difficulty swallowing, urticaria, difficulty breathing). All these phenomena can progress to the development of anaphylactic shock.
Local reactions: swelling or inflammation at the injection site; the appearance of ischemic zones at the injection site (up to the development of tissue necrosis - with accidental intravascular injection);
Others: headaches are often observed, probably associated with the presence of epinephrine in the drug; other side effects caused by the action of epinephrine (tachycardia, arrhythmia, increased blood pressure) are extremely rare; nerve damage (up to the development of paralysis) - occurs only when the injection technique is violated.

Overdose

Symptoms: dizziness, motor restlessness, impaired consciousness, decreased blood pressure, tachycardia, bradycardia.
Treatment: When the first signs of an overdose appear during injection, it is necessary to stop administering the drug, place the patient in a horizontal position, ensure clear airways, monitor heart rate and blood pressure. If breathing is impaired - oxygen, endotracheal intubation, artificial ventilation (central analeptics are contraindicated); for convulsions - slow intravenous short-acting barbiturates with simultaneous oxygen supply and hemodynamic control; in case of severe circulatory disorders and shock - intravenous infusion of solutions of electrolytes and plasma substitutes, glucocorticosteroids, albumin; with vascular collapse and increasing bradycardia - epinephrine 0.1 mg slowly intravenously, then intravenously by drip under the control of heart rate and blood pressure; for severe tachycardia and tachyarrhythmia - intravenous beta-blockers (selective); with increased blood pressure - peripheral vasodilators. Oxygen therapy and monitoring of blood circulation parameters are necessary in all cases. Interaction with other drugs
The hypertensive effect of sympathomimetic amines such as epinephrine can be enhanced by tricyclic antidepressants and monoamine oxidase inhibitors.
This type of interaction has been described for epinephrine and norepinephrine when used as vasoconstrictors at concentrations of 1:25,000 and 1:80,000, respectively.
The drug should not be prescribed during treatment with non-selective beta-blockers, since in this case there is a high risk of developing a hypertensive crisis and severe bradycardia.
The local anesthetic effect of articaine is enhanced and prolonged by vasoconstrictor drugs.

Ubistesin is a drug that has a local anesthetic effect. The drug is one of the most modern and effective representatives of the group of local anesthetics.

Ease of use, a small number of preservatives and adverse reactions allowed Ubistezin to become the option of choice in the presence of somatic pathologies in the patient. Dentists widely use anesthetic for and.

Components of anesthetic and features of carpules

The drug contains:

articaine hydrochloride 40 mg;
epinephrine hydrochloride or adrenaline;
water for injections;
sodium chloride;
sodium sulfite.

The product is available in 2 versions: Ubistezin 1/200000 and Forte version 1/100000. They differ in the amount of vasoconstrictor substance. In the first case, the amount of epinephrine will be 5 µg/ml, and in the second - 10 µg/ml.

The anesthetic itself is produced in the form of 1.7 ml carpules. They are packaged in special tin cans with a soft surface on the inside.

Thanks to this, integrity is maintained during transportation, and further storage proceeds without any difficulties.

Moreover, each individual carpule has its own characteristics:

Coating the inner surface with a special silicone layer. As a result, the injection becomes smooth and controlled, the piston moves more gently, and the amount of force applied is much less.
All necessary information is marked on the carpule with marking tape, which replaced glass printing. Accordingly, the risk of damage from fragments in the event of its destruction has been reduced. This point is very important when carrying out, since the pressure exerted in this case is very high.

Pharmacological properties

All properties of the drug are achieved due to the main active ingredients: articaine and epinephrine.

Articaine is an amide-type local anesthetic. Its effect occurs within 2-3 minutes after administration and lasts approximately 50-60 minutes. Compared to older substances, for example, novocaine or lidocaine, the effect of articaine is 2 times stronger.

It is also eliminated from the body faster, does not increase wound healing time and is less toxic. Therefore, Ubistezin can be used by elderly people, pregnant women and children over 5 years of age.

Epinephrine is responsible for blood vessels. It has a vasoconstrictor effect, which significantly increases the time of the anesthetic effect.

Thanks to this component, the drug has high penetrating ability and almost completely binds to blood plasma proteins. This ensures the safety of its use in the treatment of pregnant and lactating women. The medicine does not pass into breast milk and does not cross the placenta.

Scope of application and contraindications

The anesthetic is used for and during the following dental procedures:

Ubistezin and especially Ubistezin Forte cannot be used for:

individual intolerance to the components of the drug;
paroxysmal ventricular tachycardia and atrial fibrillation;
hyperthyroidism;
angle-closure glaucoma;
the use of non-selective beta-blockers;
severe forms of liver failure;
bronchial asthma;
treatment with tricyclic antidepressants and drugs containing monoamine oxidase;
cardiogenic shock;
methemoglobinemia;
B12 deficiency anemia.

Conditions in which the product should be used with caution:

cholinesterase deficiency;
kidney failure;
diabetes;
hypertonic disease;
children under 4 years old.

How is the medicine administered and in what dosages?

The method of administration and dosage of the anesthetic depends on the goals of the dentist:

The maximum dosage is calculated from the ratio of 7 mg of articaine per 1 kg of body weight. One capsule contains 40 mg of anesthetic.

Application in special cases

Due to the low vasoconstrictor content, the risk of side effects is quite low. Therefore, the use of the drug in the treatment of patients with diseases of the cardiovascular system is not excluded.

During pregnancy, Ubistezin can be used; it does not have a harmful effect on the fetus. Only in rare cases does bradycardia develop. The drug of choice in such situations is a drug at a dosage of 1/200,000.

special instructions

Intravenous administration is completely excluded. To prevent such situations from occurring, an aspiration test should be performed.

The drug should not be used in areas of pronounced inflammatory process. It is recommended to administer the product near the inflamed area.

To prevent the development of infections, needles and syringes must be changed during each withdrawal from a vial or ampoule. Opened carpules are not reused. The use of damaged cartridges is also excluded.

Possible adverse reactions and cases of overdose

Ubistezin can have the following inhibitory effects on body systems:

Effect on the central nervous system. The patient may develop headache, loss of consciousness, breathing problems, and convulsions.
Effect on the gastrointestinal tract. In some cases, nausea, vomiting and diarrhea occur.
Changes in the functioning of the sensory organs are rarely observed. Sometimes, if the anesthesia technique is violated, diplopia or temporary impairment of visual acuity is possible.
Effect on the heart and blood vessels. There is a possibility of a decrease in blood pressure, tachycardia or bradycardia, arrhythmia.
Allergic reactions. The skin may become red and itchy. There is also a risk of developing allergic conjunctivitis and rhinitis. More serious complications include angioedema and anaphylactic shock.
Local manifestations. Swelling or an inflammatory reaction may occur at the injection site. If the anesthesia technique is violated, ischemic zones appear and damage to the nerve trunk occurs.

Symptoms of excessive drug administration are:

dizziness;
change in consciousness;
lowering blood pressure levels;
tachy- or bradycardia.

What to do if unwanted reactions occur:

immediate stop of drug administration;
giving the patient a horizontal position;
provision of oxygen;
monitoring pulse and blood pressure;
if breathing is impaired, the introduction of air ducts and artificial ventilation are recommended;
if convulsions occur, barbiturates are used;
circulatory disorders are corrected with electrolyte solutions;
bradycardia is treated with intravenous administration of 0.1 mg of adrenaline;
for tachycardia, selective beta-blockers are used;
pressure is reduced by peripheral vasodilators.

Cost and analogues

The price of the Ubistezin Forte solution is 1500-2000 rubles per 50 capsules, the drug in a dosage of 1/200000 is 1800-2200 rubles per pack.

The following drugs have similar pharmacological properties:

In 1 ml of solution articaine hydrochloride - 40 mg, epinephrine hydrochloride - 0.006 mg, which corresponds to 0.005 mg . Water for injection, sodium chloride, sodium sulfite, as excipients.

Release form

Solution in carpules in a metal container.

pharmachologic effect

Local anesthetic.

Pharmacodynamics and pharmacokinetics

Pharmacodynamics

A combined drug intended for local anesthesia for minor surgical interventions, including dentistry . Its action is determined by the components included in its composition.

Pharmacokinetics

Articaine has high penetrating ability. 95% protein bound. It practically does not penetrate the placental barrier and is not excreted in a woman’s milk. The half-life is 22-25 minutes.

Indications for use

Anesthesia for minor dental procedures:

uncomplicated tooth extraction;
filling carious teeth;
preparation for prosthetics (grinding of teeth).

For (retrobulbar , intercostal , paravertebral ), blockades (trigeminal nerve, stellate ganglion, brachial plexus, external genitalia).

Contraindications

hypersensitivity to components;
paroxysmal tachycardia ;
and hypersensitivity to sulfites;
angle-closure glaucoma ;
concomitant therapy with non-selective beta blockers , tricyclic antidepressants;
heavy liver failure ;
cardiogenic shock ;

Use caution if you have the following diseases and conditions:

chronic heart failure ;
inflammation in the area of anesthesia;
weakened patients;
elderly age.

Side effects

headache, muscle pain, impaired breathing and consciousness (loss of consciousness is possible), muscle twitching, generalized convulsions are possible;
nausea, vomiting;
“cloudedness” in the eyes;
drop in blood pressure, tachycardia , depression of cardiovascular activity;
redness of the skin, itching, swelling of the lips, glottis;
swelling at the injection site;
nerve damage.

Instructions for Ubistezin (Method and dosage)

It is used for practically healthy patients during dental procedures. On average, 1–1.5 carpules are used at a time, which corresponds to 2–3 ml of solution. A maximum of 2 carpules is administered over 2 hours, a more accurate dose calculation is 7 mg/kg.

Uncomplicated tooth extraction- under the mucous membrane 1.7 ml per tooth. With a palatal incision 0.1 ml. Anesthesia for tonsillectomy- 5-10 ml per tonsil, with suturing the perineum- 5-15 ml.

At conduction anesthesia(retrobulbar, intercostal, paravertebral, epidural, sacral), blockades (paracervical, trigeminal nerve, stellate ganglion, brachial plexus) from 1 to 30 ml of anesthetic are used depending on the location and volume of anesthesia.

Instructions for Ubistezin forte

Ubistezin forte contains articaina 40 mg, a dose of epinephrine 2 times more -10 mcg/ml. It is an anesthetic with a moderate vasoconstrictor content and is the most effective of the painkillers. Ubistezin forte is used for long and complex extractions of large groups of teeth. Recommended for use in apparently healthy patients. You can use 1–2 carpules at a time, which corresponds to 2–4 ml of solution. The maximum you can administer is 2.5–3 carpules over 2 hours.

Overdose

Overdose is manifested by symptoms: dizziness, tachycardia or bradycardia, impaired consciousness, anxiety, decreased blood pressure.

It is necessary to stop the manipulation, lie the patient down and restore adequate airway patency, monitor blood pressure and heart rate. Inhalation of oxygen and artificial ventilation are indicated. In the presence of seizures administered intravenously barbiturates ; at shocked- infusion electrolytes , glucocorticosteroids ; at vascular collapse- intravenously 0.1 mg; at tachycardia- intravenously selective beta blockers ; at increased pressure- peripheral vasodilators .

Interaction

The anesthetic effect of the drug is enhanced by vasoconstrictor drugs.

Ubistezin should not be used during therapy with non-selective beta-blockers, as there is a risk hypertensive crisis And bradycardia .

Hypertensive effect epinephrine intensifies tricyclic antidepressants .

Terms of sale

Dispensed by prescription.

Storage conditions

At temperatures up to 250 C.

Best before date

Analogs

Level 4 ATX code matches:

Alfacaine , Brilocaine-adrenaline , Brilocaine-adrenalineforte , Primacaine , Ultracaine suprarenine , Cytokartin .

Ubistezin during pregnancy

During pregnancy, this drug can be used. It does not cross the placental barrier, therefore it is a safe anesthetic during this period. Does not have a negative effect on the fetus with any technique of use and dosage. Is only possible bradycardia in the fetus. A nursing mother does not need to interrupt breastfeeding, since the active substances are not excreted in milk in quantities significant for the baby.